| || |
Jannette M. Dufour, Ph.D.
Ph.D. Genetics and Cell Biology
Washington State University, 1999
Department of Cell Biology and Biochemistry
Texas Tech University Health Sciences Center
3601 Fourth Street, STOP 6540
Lubbock, TX 79430
Phone: (806) 743-2700 X241
FAX: (806) 743-2990
Sertoli cells, Immune privilege, Transplantation, Diabetes, Islets, Gene therapy, Cell Therapy.
Current research is focused on the use of immunoprotective Sertoli cells in transplantation.
Transplantation of genetically modified, immune-privileged Sertoli cells
In this project, we are evaluating the feasibility of using immune-privileged Sertoli cells as a vehicle to deliver therapeutically relevant proteins. Specifically, the ability of insulin-expressing Sertoli cells to normalize blood glucose levels long-term in diabetic mice and survive after transplantation across immunological barriers.
Immune-privileged Sertoli cells as a treatment for diabetes
The objective of this project is to determine the mechanism by which Sertoli cells protect co-transplanted pancreatic islets in order to increase knowledge of what is necessary to create an immune privileged site and ultimately to improve outcomes of islet transplantation.
- Kaur G, Long CR, Dufour JM. 2012 Genetically engineered immune privileged Sertoli cells – a new road to cell based gene therapy. Spermatogenesis 2:23-31. Cover photo [PubMed]
- Doyle TJ, Kaur G, Putrevu SM, Dyson EL, Dyson M, McCunniff WT, Kim KH, Dufour JM. 2012 Potential genes and pathways that confer immune privilege: immunoprotective properties of Sertoli cell-enriched testicular cells. Biology of Reproduction 86:1-14. [PubMed]
- Kaur G, Dufour JM. 2012 Editorial: Cell lines – Valuable tools or useless artifacts. Spermatogenesis 2:1-5. [PubMed]
- Mital P, Hinton BT, Dufour JM. 2011 The blood-testis and blood-epididymal barriers are more than just their tight junctions. Biology of Reproduction 84:851–858. [PubMed]
- Halley KR, Dyson EL, Kaur G, Mital P, Uong P, Dass B, Dufour JM. 2010 Delivery of a therapeutic protein by immune privileged Sertoli cells. Cell Transplantation 19:1645-1657. [PubMed]
- Mital P, Kaur G, Dufour JM. 2010 Immunoprotective Sertoli cells: Making allogeneic and xenogeneic transplantation feasible. Reproduction 139:495-504. [PubMed]
- Dufour JM, Lord SJ, Kin T, Rayat GR, Dixon DE, Bleackley RC, Korbutt GS, Rajotte RV. 2008 Comparison of successful and unsuccessful islet/Sertoli cell co-transplant grafts in streptozotocin induced diabetic mice. Cell Transplantation 16:1029-1038. [PubMed]
- Dufour JM, Dass B, Halley K, Korbutt GS, Dixon DE, Rajotte RV. 2008 Sertoli cell line lacks the immunoprotective properties associated with primary Sertoli cells. Cell Transplantation 17:525-534. Cover photo [PubMed]
- Lord SJ, Sipione S, Motyka B, Ewen C, Shostak I, Rayat GR, Dufour JM, Korbutt GS, Rajotte RV, Bleackley RC. 2006 Identification of a novel human granzyme B inhibitor secreted by cultured Sertoli cells. Journal of Immunology 177:5051-5058. [PubMed]
- Dufour JM, Hamilton M, Rajotte RV, Korbutt GS. 2005 Neonatal porcine Sertoli cells inhibit human natural antibody mediated lysis. Biology of Reproduction 72:1224-1231. [PubMed]
- Dufour JM, Rajotte RV, Zimmerman M, Rezania A, Kin T, Dixon DE, Korbutt GS. 2005 Development of an ectopic site for islet transplantation using biodegradable scaffolds. Tissue Engineering 9/10:1323-1331. [PubMed]
- Kin T, Korbutt GS, Kobayashi T, Dufour JM, Rajotte. 2005 Reversal of diabetes in pancreatectomized pigs after transplantation of neonatal porcine islets. Diabetes 54:1032-1039. [PubMed]
- Dufour JM, Hemendinger R, Halberstadt CR, Gores P, Emerich DF, Korbutt GS, Rajotte RV. 2004 Genetically engineered Sertoli cells are able to survive allogeneic transplantation. Gene Therapy 11:694-700. [PubMed]
- Dufour JM, Rajotte RV, Seeberger K, Kin T, Korbutt GS. 2003 Long-term survival of neonatal porcine Sertoli cells in non- immunosuppressed rats. Xenotransplantation. 10:577-586. [PubMed]